ArticleWorld journal of urology2012
Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasia.
Article in World journal of urology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Using EQ-5D-3L and OAB-5D to assess changes in the health-related quality of life of men with lower urinary tract symptoms associated with benign prostatic hyperplasia.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2017Trial
- Transient and persistent urinary incontinence after thulium fiber laser enucleation of the prostate (ThuFLEP): long-term trends and predictive factors in a real-world cohort.World journal of urology · 2026Article
- Quantification of the Role of TeupolMedicina (Kaunas, Lithuania) · 2025Observational
- Development of a clinical decision support tool for Primary care Management of lower Urinary tract Symptoms in men: the PriMUS study.Health technology assessment (Winchester, England) · 2025Article
- Article
- Effect of Self-Training Using Virtual Reality Head-Mounted Display Simulator on the Acquisition of Holmium Laser Enucleation of the Prostate Surgical Skills.International neurourology journal · 2024Article
- Phytomedicines in Pharmacotherapy of LUTS/BPH - What Do Patients Think?Patient preference and adherence · 2024Article
- Clinical outcomes of withdrawing one medication from long-term combination therapy comprising α-blocker and 5α-reductase inhibitor for benign prostatic hyperplasia.International urology and nephrology · 2023Article
- Patients' Preferences and Expectations in Overactive Bladder: A Systematic Review.Journal of clinical medicine · 2023Review
- Persistence to Medications for Benign Prostatic Hyperplasia/Benign Prostatic Obstruction-Associated Lower Urinary Tract Symptoms in the ASL TO4 Regione Piemonte (Italy).Healthcare (Basel, Switzerland) · 2022Article
- The Role of Combination Therapy with α-Blockers and Hexanic Extract ofJournal of clinical medicine · 2022Review
- Mid-term functional outcomes of extraperitoneal robot-assisted simple prostatectomy: a single centre experience.Journal of robotic surgery · 2022Article
- Factors associated with quality of life in patients with benign prostatic hyperplasia, 2009-2016.Medicine · 2022Article
- Association between benign prostatic hyperplasia and suicide in South Korea: A nationwide retrospective cohort study.PloS one · 2022Article
- Managing lower urinary tract symptoms in primary care: qualitative study of GPs' and patients' experiences.The British journal of general practice : the journal of the Royal College of General Practitioners · 2021Article
- An evaluation of the federal adverse events reporting system data on adverse effects of 5-alpha reductase inhibitors.World journal of urology · 2021Article
- Quality of life with pharmacological treatment in patients with benign prostatic enlargement: results from the Evolution European Prospective Multicenter Multi-National Registry Study.World journal of urology · 2021Observational
- Safety and effectiveness of mirabegron in male patients with overactive bladder with or without benign prostatic hyperplasia: A Japanese post-marketing study.Lower urinary tract symptoms · 2021Article
- Clinical Benefit of Tamsulosin and the Hexanic Extract of Serenoa Repens, in Combination or as Monotherapy, in Patients with Moderate/Severe LUTS-BPH: A Subset Analysis of the QUALIPROST Study.Journal of clinical medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study's aim was to describe and evaluate outcomes of medical strategies used for lower urinary tract symptoms (LUTS) treatment in general practice and to assess impact of LUTS on patients' general health-related quality of life (HRQoL).
methodsThis cross-sectional observational study was conducted by French general practitioners. Eligible patients were males aged ≥50 years, diagnosed for at least one year and currently treated for LUTS due to benign prostatic hyperplasia (BPH). Several validated questionnaires were documented by patients to assess severity of LUTS (IPSS), specific quality of life (IPSS-Q8), impact of LUTS (BII), LUTS evolution (VNS) and general HRQoL (EQ-5D).
resultsAmong 1,098 patients included, 82.7% were treated with monotherapies and 17.3% with combinations. Mean treatment duration was 5.2 ± 3.2 years, and 47.2% of patients had at least one treatment modification since initiation. Patients reported diminished quality of life (IPSS-Q8 ≥3) (42.3%), persisting symptoms (IPSS-score ≥12) (35.5%), symptoms worsening (VNS-score ≤-1) (18.8%) and high bother (BII-score ≥9) (2.6%). Globally, 52.8% had at least one of these unsatisfactory outcomes. Regarding general HRQoL, mean EQ-5D utility significantly decreased with LUTS severity (mild: 0.90 ± 0.12; moderate: 0.81 ± 0.21; and severe symptoms: 0.73 ± 0.25; P < 0.001). As well, all five-dimensions of EQ-5D were significantly altered in patients with moderate-to-severe LUTS (<0.001), especially 'Pain/Discomfort' and 'Anxiety/Depression'. In multivariate analyses including age and comorbidities, EQ-5D utility index remained negatively associated with each additional unit in the IPSS-score.
conclusionsThis study shows that around half of BPH patients medically treated report unsatisfactory outcomes, suggesting consequential unmet medical needs in general practice. Also, moderate-to-severe LUTS significantly impact on general HRQoL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.